ISSN 1662-4009 (online)

ey0015.10-13 | Comorbidities – short and long-term complications | ESPEYB15

10.13 Prevalence of celiac disease in 52,721 youth with T1DM: international comparison across three continents

ME Craig , N Prinz , CT Boyle , FM Campbell , TW Jones , SE Hofer , JH Simmons , N Holman , E Tham , E Fröhlich-Reiterer , S DuBose , H Thornton , B King , DM Maahs , RW Holl , JT Warner

To read the full abstract: Diabetes Care. 2017;40:1034-1040Researchers from The Children’s Hospital at Westmead, Sydney, Australia as well as scientists from institutions from three different continents, America, Europe and Australia have combined their data from large diabetes registries in order to: examine the prevalence of celiac disease (CD) in populations of patients with T1DM; investigat...

ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20

8.1. Effect of Verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial

GP Forlenza , J McVean , RW Beck , C Bauza , R Bailey , B Buckingham , LA DiMeglio , JL Sherr , M Clements , A Neyman , C Evans-Molina , EK Sims , LH Messer , L Ekhlaspour , R McDonough , M Van Name , D Rojas , S Beasley , S DuBose , C Kollman , A Moran , CLVer Study Group

Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 7–17 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...